Document Detail


Recent i.v.-drug users with chronic hepatitis C can be efficiently treated with daily high dose induction therapy using consensus interferon: an open-label pilot study.
MedLine Citation:
PMID:  17278224     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
AIM: To investigate the use of high dose consensus-interferon in combination with ribavirin in former iv drug users infected with hepatitis C.
METHODS: We started, before pegylated (PEG)-interferons were available, an open-label study to investigate the efficacy and tolerability of high dose induction therapy with consensus interferon (CIFN) and ribavirin in treatment of naiive patients with chronic hepatitis C. Fifty-eight patients who were former iv drug users, were enrolled receiving 18 microg of CIFN daily for 8 wk, followed by 9 mug daily for up to wk 24 or 48 and 800 mg of ribavirin daily. End point of the study was tolerability and eradication of the virus at wk 48 and sustained virological response at wk 72.
RESULTS: More than 62% of patients responded to the treatment with CIFN at wk 24 or 48, respectively, showing a negative qualitative PCR [genotype 1 fourteen patients (56%), genotype 2 five (50%), genotype 3 thirteen (87%), genotype 4 four (50%)]. Forty-eight percent of genotype 1 patients showed sustained virological response (SVR) six months after the treatment.
CONCLUSION: CIFN on a daily basis is well tolerated and side effects like leuko- and thrombocytopenia are moderate. End of therapy (EOT) rates are slightly lower than the newer standard therapy with pegylated interferons. CIFN on a daily basis might be a favourable therapy regimen for patients with GT1 and high viral load or for non-responders after failure of standard therapy.
Authors:
Th Witthoeft; M Fuchs; D Ludwig
Related Documents :
7832194 - Role of interferon alpha-2a in the treatment of polycythemia vera.
11642634 - Lamivudine and interferon-alpha combination treatment of childhood patients with chroni...
11679984 - Recurrent hepatitis c after liver transplantation: a nonrandomized trial of interferon ...
11673814 - Antiviral potency of haart regimens and clinical success are not strictly coupled in re...
8253004 - Strictureplasty for ileocolic anastomotic strictures in crohn's disease.
1817074 - How effective is the combined activator-headgear treatment?
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  World journal of gastroenterology : WJG     Volume:  13     ISSN:  1007-9327     ISO Abbreviation:  World J. Gastroenterol.     Publication Date:  2007 Jan 
Date Detail:
Created Date:  2007-02-05     Completed Date:  2007-03-20     Revised Date:  2014-07-02    
Medline Journal Info:
Nlm Unique ID:  100883448     Medline TA:  World J Gastroenterol     Country:  China    
Other Details:
Languages:  eng     Pagination:  579-84     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Alanine Transaminase / blood
Antiviral Agents / administration & dosage*
Drug Therapy, Combination
Female
Genotype
Hepacivirus / classification
Hepatitis C, Chronic / drug therapy*,  psychology
Humans
Interferon Type I / administration & dosage*,  adverse effects
Interferon-alpha
Male
Middle Aged
Pilot Projects
Quality of Life
Recombinant Proteins
Ribavirin / administration & dosage*
Substance Abuse, Intravenous / complications*
Chemical
Reg. No./Substance:
0/Antiviral Agents; 0/Interferon Type I; 0/Interferon-alpha; 0/Recombinant Proteins; 118390-30-0/interferon alfacon-1; 49717AWG6K/Ribavirin; EC 2.6.1.2/Alanine Transaminase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Gastrointestinal symptoms in a Japanese population: a health diary study.
Next Document:  Elastic band ligation of hemorrhoids: flexible gastroscope or rigid proctoscope?